A hereditary cancer consultation clinic.

Henry T. Lynch, M. L. Fitzsimmons, J. Lynch, P. Watson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

There is a significant hiatus between existing knowledge about hereditary forms of cancer and the application of this information at the bedside. We believe that the HCCC concept will effectively bridge this gap between medical knowledge and its service application. Priority areas for assuring long-range success of this mission will require: a) greater public and physician awareness of the hereditary portion of the total cancer problem; b) generation of cost-benefit information relevant to the surveillance and management of patients at risk for hereditary cancer so that third party carriers might be more responsive to patient needs: c) enhancement of patient/family compliance with surveillance/management protocols leading to early detection of cancer and improved survival; and d) research into biomarkers which demonstrate acceptable sensitivity and specificity for the cancer-prone genotype, one day enabling identification of the deleterious gene(s). Thus, we may achieve the ultimate goal of identifying biochemical agents which will effectively ameliorate the deleterious products of the cancer-prone gene(s), improve clinical outlook, or even prevent cancer expression.

Original languageEnglish
Pages (from-to)351-359
Number of pages9
JournalThe Nebraska medical journal
Volume74
Issue number12
StatePublished - Dec 1989
Externally publishedYes

Fingerprint

Referral and Consultation
Neoplasms
Neoplasm Genes
Patient Compliance
Early Detection of Cancer
Cost-Benefit Analysis
Biomarkers
Genotype
Physicians
Sensitivity and Specificity
Survival
Research
Genes

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lynch, H. T., Fitzsimmons, M. L., Lynch, J., & Watson, P. (1989). A hereditary cancer consultation clinic. The Nebraska medical journal, 74(12), 351-359.

A hereditary cancer consultation clinic. / Lynch, Henry T.; Fitzsimmons, M. L.; Lynch, J.; Watson, P.

In: The Nebraska medical journal, Vol. 74, No. 12, 12.1989, p. 351-359.

Research output: Contribution to journalArticle

Lynch, HT, Fitzsimmons, ML, Lynch, J & Watson, P 1989, 'A hereditary cancer consultation clinic.', The Nebraska medical journal, vol. 74, no. 12, pp. 351-359.
Lynch HT, Fitzsimmons ML, Lynch J, Watson P. A hereditary cancer consultation clinic. The Nebraska medical journal. 1989 Dec;74(12):351-359.
Lynch, Henry T. ; Fitzsimmons, M. L. ; Lynch, J. ; Watson, P. / A hereditary cancer consultation clinic. In: The Nebraska medical journal. 1989 ; Vol. 74, No. 12. pp. 351-359.
@article{3d9375cc8765479c93c4da406279490d,
title = "A hereditary cancer consultation clinic.",
abstract = "There is a significant hiatus between existing knowledge about hereditary forms of cancer and the application of this information at the bedside. We believe that the HCCC concept will effectively bridge this gap between medical knowledge and its service application. Priority areas for assuring long-range success of this mission will require: a) greater public and physician awareness of the hereditary portion of the total cancer problem; b) generation of cost-benefit information relevant to the surveillance and management of patients at risk for hereditary cancer so that third party carriers might be more responsive to patient needs: c) enhancement of patient/family compliance with surveillance/management protocols leading to early detection of cancer and improved survival; and d) research into biomarkers which demonstrate acceptable sensitivity and specificity for the cancer-prone genotype, one day enabling identification of the deleterious gene(s). Thus, we may achieve the ultimate goal of identifying biochemical agents which will effectively ameliorate the deleterious products of the cancer-prone gene(s), improve clinical outlook, or even prevent cancer expression.",
author = "Lynch, {Henry T.} and Fitzsimmons, {M. L.} and J. Lynch and P. Watson",
year = "1989",
month = "12",
language = "English",
volume = "74",
pages = "351--359",
journal = "The Nebraska medical journal",
issn = "0091-6730",
publisher = "Nebraska State Medical Association",
number = "12",

}

TY - JOUR

T1 - A hereditary cancer consultation clinic.

AU - Lynch, Henry T.

AU - Fitzsimmons, M. L.

AU - Lynch, J.

AU - Watson, P.

PY - 1989/12

Y1 - 1989/12

N2 - There is a significant hiatus between existing knowledge about hereditary forms of cancer and the application of this information at the bedside. We believe that the HCCC concept will effectively bridge this gap between medical knowledge and its service application. Priority areas for assuring long-range success of this mission will require: a) greater public and physician awareness of the hereditary portion of the total cancer problem; b) generation of cost-benefit information relevant to the surveillance and management of patients at risk for hereditary cancer so that third party carriers might be more responsive to patient needs: c) enhancement of patient/family compliance with surveillance/management protocols leading to early detection of cancer and improved survival; and d) research into biomarkers which demonstrate acceptable sensitivity and specificity for the cancer-prone genotype, one day enabling identification of the deleterious gene(s). Thus, we may achieve the ultimate goal of identifying biochemical agents which will effectively ameliorate the deleterious products of the cancer-prone gene(s), improve clinical outlook, or even prevent cancer expression.

AB - There is a significant hiatus between existing knowledge about hereditary forms of cancer and the application of this information at the bedside. We believe that the HCCC concept will effectively bridge this gap between medical knowledge and its service application. Priority areas for assuring long-range success of this mission will require: a) greater public and physician awareness of the hereditary portion of the total cancer problem; b) generation of cost-benefit information relevant to the surveillance and management of patients at risk for hereditary cancer so that third party carriers might be more responsive to patient needs: c) enhancement of patient/family compliance with surveillance/management protocols leading to early detection of cancer and improved survival; and d) research into biomarkers which demonstrate acceptable sensitivity and specificity for the cancer-prone genotype, one day enabling identification of the deleterious gene(s). Thus, we may achieve the ultimate goal of identifying biochemical agents which will effectively ameliorate the deleterious products of the cancer-prone gene(s), improve clinical outlook, or even prevent cancer expression.

UR - http://www.scopus.com/inward/record.url?scp=0024795124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024795124&partnerID=8YFLogxK

M3 - Article

C2 - 2608150

AN - SCOPUS:0024795124

VL - 74

SP - 351

EP - 359

JO - The Nebraska medical journal

JF - The Nebraska medical journal

SN - 0091-6730

IS - 12

ER -